|
US7238673B2
(en)
|
1989-03-31 |
2007-07-03 |
The Regents Of The University Of Michigan |
Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
|
|
US7745416B2
(en)
*
|
1995-04-11 |
2010-06-29 |
The Regents Of The University Of California |
Method for in vivo regulation of cardiac muscle contractility
|
|
WO1996040272A1
(fr)
*
|
1995-06-07 |
1996-12-19 |
University Of North Carolina At Chapel Hill |
Transduction de myoblastes par vecteurs de virus adeno-associes
|
|
US20010009904A1
(en)
*
|
1997-12-30 |
2001-07-26 |
Jon A. Wolff |
Process of delivering a polynucleotide to a cell via the vascular system
|
|
US20060088938A1
(en)
*
|
1995-12-15 |
2006-04-27 |
Mitchell Lloyd G |
Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
|
|
US20030027250A1
(en)
*
|
1995-12-15 |
2003-02-06 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
|
US20020193580A1
(en)
*
|
1995-12-15 |
2002-12-19 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
|
US5846528A
(en)
*
|
1996-01-18 |
1998-12-08 |
Avigen, Inc. |
Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
|
|
US5858351A
(en)
*
|
1996-01-18 |
1999-01-12 |
Avigen, Inc. |
Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
|
|
US5962313A
(en)
*
|
1996-01-18 |
1999-10-05 |
Avigen, Inc. |
Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
|
|
AU723497C
(en)
*
|
1996-09-06 |
2001-10-11 |
Trustees Of The University Of Pennsylvania, The |
Method for recombinant adeno-associated virus-directed gene therapy
|
|
US20020037867A1
(en)
*
|
1999-02-26 |
2002-03-28 |
James M. Wilson |
Method for recombinant adeno-associated virus-directed gene therapy
|
|
US5866552A
(en)
*
|
1996-09-06 |
1999-02-02 |
The Trustees Of The University Of Pennsylvania |
Method for expressing a gene in the absence of an immune response
|
|
US6242426B1
(en)
*
|
1997-07-25 |
2001-06-05 |
Avigen, Inc. |
Induction of immune response to antigens expressed by recombinant adeno-associated virus
|
|
CA2297490A1
(fr)
*
|
1997-07-31 |
1999-02-11 |
Chiron Corporation |
Procede permettant de readministrer un vecteur viral adeno-associe via l'immunodepression de l'hote
|
|
US6995006B2
(en)
*
|
1997-09-05 |
2006-02-07 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
|
US6346415B1
(en)
|
1997-10-21 |
2002-02-12 |
Targeted Genetics Corporation |
Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
|
|
CA2305768A1
(fr)
*
|
1997-10-29 |
2000-02-24 |
Genzyme Corporation |
Compositions et procedes pour traiter les maladies lysosomiales
|
|
US6953690B1
(en)
|
1998-03-20 |
2005-10-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
|
US6759237B1
(en)
|
1998-11-05 |
2004-07-06 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
|
|
ATE454445T1
(de)
|
1998-11-10 |
2010-01-15 |
Univ North Carolina |
Virusvektoren und verfahren für ihre herstellung und verabreichung.
|
|
US6303362B1
(en)
|
1998-11-19 |
2001-10-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adenoviral vector and methods for making and using the same
|
|
WO2000031267A1
(fr)
*
|
1998-11-20 |
2000-06-02 |
The Autonomous University Of Barcelona |
Production d'insuline par des cellules musculaires genetiquement modifiees
|
|
US7078387B1
(en)
|
1998-12-28 |
2006-07-18 |
Arch Development Corp. |
Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
|
|
US6509150B1
(en)
*
|
1999-03-05 |
2003-01-21 |
Universite De Nantes |
Compositions and methods for recombinant Adeno-Associated Virus production
|
|
JP4693244B2
(ja)
|
1999-03-18 |
2011-06-01 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
|
|
WO2001036603A2
(fr)
*
|
1999-11-17 |
2001-05-25 |
Avigen, Inc. |
Virions de virus adeno-associes recombinants destines au traitement de maladies lysosomales
|
|
US20040204379A1
(en)
*
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
|
US20040126774A1
(en)
*
|
2001-01-08 |
2004-07-01 |
Mitchell Lioyd G. |
Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
|
|
WO2002081648A2
(fr)
*
|
2001-04-09 |
2002-10-17 |
The United States of America, represented by The Secretary, Department of Health & Human Services |
Synthese et secretion d'enzymes lysosomiales natives de recombinaison produites par le foie
|
|
CA2457694A1
(fr)
*
|
2001-08-09 |
2003-02-20 |
Cornell Research Foundation, Inc. |
Protection du facteur de croissance derive de plaquettes du myocarde
|
|
US6838285B2
(en)
|
2001-09-18 |
2005-01-04 |
Becton Dickinson |
Site specific recombinase based method for producing adenoviral vectors
|
|
US20030235555A1
(en)
*
|
2002-04-05 |
2003-12-25 |
David Shealey |
Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
|
|
US7399753B2
(en)
*
|
2002-02-25 |
2008-07-15 |
Virxsys Corporation |
Trans-splicing mediated photodynamic therapy
|
|
AU2003223780A1
(en)
*
|
2002-04-30 |
2003-11-17 |
University Of Florida |
Treatment for pompe disease
|
|
WO2003092594A2
(fr)
*
|
2002-04-30 |
2003-11-13 |
Duke University |
Vecteurs viraux et procedes de production et d'utilisation de ceux-ci
|
|
JP2005536231A
(ja)
*
|
2002-05-08 |
2005-12-02 |
イントロン，インコーポレーテッド |
アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型ｒｎａトランススプライシングの使用
|
|
DE60333032D1
(de)
*
|
2002-10-23 |
2010-07-29 |
Virxsys Corp |
Screening-verfahren zur identifizierung wirksamer prä-trans-spleissmoleküle
|
|
US7803365B2
(en)
*
|
2002-12-02 |
2010-09-28 |
Biovec, Llc |
Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
|
|
US9388427B2
(en)
*
|
2002-12-02 |
2016-07-12 |
Biovec, Llc |
In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
|
|
JP5433133B2
(ja)
*
|
2003-01-22 |
2014-03-05 |
デューク・ユニヴァーシティ |
リソソームポリペプチドを発現するための改善された構築物
|
|
US20050106124A1
(en)
*
|
2003-02-25 |
2005-05-19 |
Sehgal Lakshman R. |
Therapeutic applications of thrombomodulin gene via viral and non-viral vectors
|
|
DK3470535T3
(da)
|
2003-06-24 |
2020-06-29 |
Genomic Health Inc |
Forudsigelse af sandsynlighed for tilbagevenden af cancer
|
|
WO2005003323A2
(fr)
*
|
2003-07-01 |
2005-01-13 |
The Regents Of The University Of California |
Utilisation de proteines de fixation au calcium pour ameliorer la fonction contractile cardiaque
|
|
CN1906162B
(zh)
*
|
2003-11-12 |
2012-05-23 |
阿米库斯治疗学公司 |
用于治疗戈谢病的羟基哌啶衍生物
|
|
US7129049B2
(en)
*
|
2003-12-22 |
2006-10-31 |
Regents Of The University Of Minnesota |
Method of detecting equine glycogen storage disease IV
|
|
EP1716165A4
(fr)
*
|
2004-01-23 |
2008-06-18 |
Virxsys Corp |
Expression d'apoliproteine a1 (apoa-1) et variants au moyen de transepissage d'arn induit par complexe d'epissage
|
|
US7968334B2
(en)
*
|
2004-01-23 |
2011-06-28 |
Virxsys Corporation |
Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
|
|
US8053232B2
(en)
*
|
2004-01-23 |
2011-11-08 |
Virxsys Corporation |
Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
|
|
WO2005077333A2
(fr)
*
|
2004-02-10 |
2005-08-25 |
University Of Florida Research Foundation, Inc. |
Administration sous forme de gel de vecteurs de virus associes aux adenovirus recombines
|
|
WO2005116224A2
(fr)
*
|
2004-05-18 |
2005-12-08 |
Children's Memorial Hospital |
Vecteurs viraux adeno-associes regules par la tetracycline pour l'administration de gene au systeme nerveux
|
|
US20060094110A1
(en)
*
|
2004-07-30 |
2006-05-04 |
Mcgarrity Gerard J |
Use of spliceosome mediated RNA trans-splicing for immunotherapy
|
|
US20060134658A1
(en)
*
|
2004-08-09 |
2006-06-22 |
Garcia-Blanco Mariano A |
Use of RNA trans-splicing for generation of interfering RNA molecules
|
|
DE102004047492B4
(de)
*
|
2004-09-23 |
2006-07-20 |
Jost-Werke Gmbh & Co. Kg |
Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
|
|
US7871795B2
(en)
|
2004-10-08 |
2011-01-18 |
Virxsys Corporation |
Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
|
|
AU2005326784B2
(en)
*
|
2004-10-08 |
2012-03-15 |
Virxsys Corporation |
Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production
|
|
WO2006066066A2
(fr)
*
|
2004-12-15 |
2006-06-22 |
University Of North Carolina At Chapel Hill |
Vecteurs chimeriques
|
|
KR20090035711A
(ko)
*
|
2006-07-25 |
2009-04-10 |
셀라돈 코포레이션 |
유전자 치료를 위한 아데노-관련 바이러스 벡터의 전방 심외막 관상에의 연장 주입
|
|
US20120322861A1
(en)
|
2007-02-23 |
2012-12-20 |
Barry John Byrne |
Compositions and Methods for Treating Diseases
|
|
EP2132309A4
(fr)
*
|
2007-02-23 |
2011-01-05 |
Univ Florida |
Compositions et procédés pour le traitement de maladies liées au stockage du glycogène
|
|
CN101977632A
(zh)
*
|
2008-02-19 |
2011-02-16 |
塞拉东公司 |
用于增强病毒载体于心肌中的摄取的组合物
|
|
PT2659904E
(pt)
|
2008-06-26 |
2016-01-22 |
Orphazyme Aps |
Uso da hsp70 como um regulador da atividade enzimática
|
|
US8889641B2
(en)
|
2009-02-11 |
2014-11-18 |
The University Of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
|
CA2817773A1
(fr)
|
2010-11-30 |
2012-06-07 |
Orphazyme Aps |
Procedes pour accroitre l'activite cellulaire de hsp70
|
|
WO2013066438A2
(fr)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Évaluation et amélioration de la spécificité de clivage des nucléases
|
|
RU2015101276A
(ru)
|
2012-06-19 |
2016-08-10 |
Юниверсити Оф Флорида Рисерч Фаундейшн, Инк. |
Способы лечения болезней и композиции для их осуществления
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
EP3909602A1
(fr)
|
2014-04-25 |
2021-11-17 |
University of Florida Research Foundation, Inc. |
Méthodes permettant qu'un sujet reçoive des doses multiples de virus adéno-associé recombinant
|
|
EP3151866B1
(fr)
|
2014-06-09 |
2023-03-08 |
Voyager Therapeutics, Inc. |
Capsides chimériques
|
|
CA2956224A1
(fr)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Proteines cas9 comprenant des inteines dependant de ligands
|
|
WO2016041561A1
(fr)
|
2014-09-15 |
2016-03-24 |
Orphazyme Aps |
Formulation arimoclomol
|
|
CN107106689A
(zh)
|
2014-11-05 |
2017-08-29 |
沃雅戈治疗公司 |
用于治疗帕金森病的aadc多核苷酸
|
|
KR20230145206A
(ko)
|
2014-11-14 |
2023-10-17 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
CA3193811A1
(fr)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Compositions et methodes de traitement de la sclerose laterale amyotrophique (sla)
|
|
US10900053B2
(en)
|
2014-11-21 |
2021-01-26 |
University Of Florida Research Foundation, Incorporated |
Genome-modified recombinant adeno-associated virus vectors
|
|
EP3230441A4
(fr)
|
2014-12-12 |
2018-10-03 |
Voyager Therapeutics, Inc. |
Compositions et méthodes pour la production de scaav
|
|
EP3292206B8
(fr)
|
2015-05-07 |
2022-02-09 |
Takeda Pharmaceutical Company Limited |
Glucocérébrosidase therapie genique pour la maladie de parkinson
|
|
US10167457B2
(en)
|
2015-10-23 |
2019-01-01 |
President And Fellows Of Harvard College |
Nucleobase editors and uses thereof
|
|
EP3384035A4
(fr)
|
2015-12-02 |
2019-08-07 |
Voyager Therapeutics, Inc. |
Dosages pour la détection d'anticorps neutralisants de vaa
|
|
EP3442530A1
(fr)
|
2016-04-13 |
2019-02-20 |
Orphazyme A/S |
Protéines de choc thermique et homéostasie du cholestérol
|
|
MX2018012663A
(es)
|
2016-04-16 |
2019-07-08 |
Univ Florida |
Metodos para aumentar la capacidad de actividad biológica del virus adenoasociado recombinante producido mediante el sistema baculovirus.
|
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
CN109069496A
(zh)
|
2016-04-29 |
2018-12-21 |
奥菲泽米有限公司 |
用于治疗葡糖脑苷脂酶相关疾病的arimoclomol
|
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
US10584337B2
(en)
|
2016-05-18 |
2020-03-10 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
KR20220108216A
(ko)
|
2016-05-18 |
2022-08-02 |
보이저 테라퓨틱스, 인크. |
헌팅톤 질환을 치료하기 위한 조성물 및 방법
|
|
KR20230095129A
(ko)
|
2016-08-03 |
2023-06-28 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
JP7201153B2
(ja)
|
2016-08-09 |
2023-01-10 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
プログラム可能ｃａｓ９－リコンビナーゼ融合タンパク質およびその使用
|
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
EP3506817A4
(fr)
|
2016-08-30 |
2020-07-22 |
The Regents of The University of California |
Procédés de ciblage et d'administration biomédicaux, et dispositifs et systèmes pour la mise en oeuvre de ceux-ci
|
|
AU2017342543B2
(en)
|
2016-10-14 |
2024-06-27 |
President And Fellows Of Harvard College |
AAV delivery of nucleobase editors
|
|
US10745677B2
(en)
|
2016-12-23 |
2020-08-18 |
President And Fellows Of Harvard College |
Editing of CCR5 receptor gene to protect against HIV infection
|
|
EP3585883A4
(fr)
|
2017-02-21 |
2021-04-14 |
University of Florida Research Foundation, Incorporated |
Protéines des capsides aav modifiées et leurs utilisations
|
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
EP3592777A1
(fr)
|
2017-03-10 |
2020-01-15 |
President and Fellows of Harvard College |
Éditeur de base cytosine à guanine
|
|
IL269458B2
(en)
|
2017-03-23 |
2024-02-01 |
Harvard College |
Nucleic base editors that include nucleic acid programmable DNA binding proteins
|
|
CN110913866A
(zh)
|
2017-05-05 |
2020-03-24 |
沃雅戈治疗公司 |
治疗肌萎缩性侧索硬化(als)的组合物和方法
|
|
US11752181B2
(en)
|
2017-05-05 |
2023-09-12 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating Huntington's disease
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
IL271193B2
(en)
|
2017-06-07 |
2025-01-01 |
Regeneron Pharma |
Preparations and methods for internalizing enzymes
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
US11497576B2
(en)
|
2017-07-17 |
2022-11-15 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
|
WO2019028306A2
(fr)
|
2017-08-03 |
2019-02-07 |
Voyager Therapeutics, Inc. |
Compositions et procédés permettant l'administration de virus adéno-associés
|
|
EP3676376B1
(fr)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
Éditeurs de bases à haut rendement comprenant une gam
|
|
EP3687582A4
(fr)
|
2017-09-29 |
2021-07-14 |
Voyager Therapeutics, Inc. |
Sauvetage de phénotype neurologique central et périphérique de l'ataxie de friedreich par administration intraveineuse
|
|
CN111757937A
(zh)
|
2017-10-16 |
2020-10-09 |
布罗德研究所股份有限公司 |
腺苷碱基编辑器的用途
|
|
EP4454654A3
(fr)
|
2017-10-16 |
2025-02-19 |
Voyager Therapeutics, Inc. |
Traitement de la sclérose latérale amyotrophique (sla)
|
|
EP3697905A1
(fr)
|
2017-10-16 |
2020-08-26 |
Voyager Therapeutics, Inc. |
Traitement de la sclérose latérale amyotrophique (sla)
|
|
CN112040985A
(zh)
|
2018-02-07 |
2020-12-04 |
瑞泽恩制药公司 |
用于递送治疗性蛋白质的方法和组合物
|
|
JP7393766B2
(ja)
|
2018-02-28 |
2023-12-07 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
抗体回避ウイルスベクターのための方法および組成物
|
|
SG11202009450SA
(en)
|
2018-04-03 |
2020-10-29 |
Stridebio Inc |
Virus vectors for targeting ophthalmic tissues
|
|
MX2020010466A
(es)
|
2018-04-03 |
2021-01-08 |
|
Vectores de virus que evitan anticuerpos.
|
|
CN112272672A
(zh)
|
2018-04-03 |
2021-01-26 |
斯特里迪比奥公司 |
抗体逃避性病毒载体
|
|
MX2020012350A
(es)
|
2018-05-17 |
2021-01-29 |
Regeneron Pharma |
Anticuerpos anti-cd63, conjugados y usos de estos.
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
KR20210018902A
(ko)
|
2018-06-08 |
2021-02-18 |
유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 |
심근병증에 대한 aav 심장 유전자 요법
|
|
WO2019246544A2
(fr)
|
2018-06-22 |
2019-12-26 |
Asklepios Biopharmaceutical, Inc. |
Vecteurs pour l'administration de gènes qui persistent dans les cellules
|
|
JP7528066B2
(ja)
|
2018-09-28 |
2024-08-05 |
ボイジャー セラピューティクス インコーポレイテッド |
操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法
|
|
WO2020092453A1
(fr)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Éditeurs de nucléobases comprenant geocas9 et utilisations associées
|
|
DE112020001306T5
(de)
|
2019-03-19 |
2022-01-27 |
Massachusetts Institute Of Technology |
Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
|
|
EP3941929A1
(fr)
|
2019-03-21 |
2022-01-26 |
Stridebio, Inc. |
Vecteurs viraux adéno-associés recombinants
|
|
WO2020210751A1
(fr)
|
2019-04-12 |
2020-10-15 |
The Broad Institute, Inc. |
Système pour édition génomique
|
|
WO2020236982A1
(fr)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Administration d'aav d'éditeurs de nucléobases
|
|
WO2021072328A1
(fr)
|
2019-10-10 |
2021-04-15 |
The Broad Institute, Inc. |
Procédés et compositions pour le prime editing d'arn
|
|
EP4045525A1
(fr)
|
2019-10-17 |
2022-08-24 |
Stridebio, Inc. |
Vecteurs de virus adéno-associés pour le traitement de la maladie de niemann-pick de type c
|
|
CA3177481A1
(fr)
|
2020-05-08 |
2021-11-11 |
David R. Liu |
Methodes et compositions d'edition simultanee des deux brins d'une sequence nucleotidique double brin cible
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
US20230227802A1
(en)
|
2020-07-27 |
2023-07-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
CA3189878A1
(fr)
|
2020-08-19 |
2022-02-24 |
Colin O'BANION |
Vecteurs de type virus adeno-associe pour le traitement du syndrome de rett
|
|
EP4247792A1
(fr)
|
2020-11-19 |
2023-09-27 |
Zevra Denmark A/S |
Procédés de préparation de citrate d'arimoclomol et intermédiaires associés
|
|
MX2023007602A
(es)
|
2020-12-23 |
2023-09-21 |
Univ Florida |
Mayor eficiencia del empaquetamiento de vectores para terapia genica cardiaca.
|
|
US20240417719A1
(en)
|
2021-10-25 |
2024-12-19 |
The Broad Institute, Inc. |
Methods and compositions for editing a genome with prime editing and a recombinase
|
|
WO2023091949A2
(fr)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions et méthodes de traitement de troubles neurologiques liés à un déficit en bêta glucosylcéramidase
|
|
EP4504925A1
(fr)
|
2022-04-04 |
2025-02-12 |
The Broad Institute, Inc. |
Variantes de cas9 ayant des spécificités pam non canoniques et leurs utilisations
|
|
WO2023212715A1
(fr)
|
2022-04-28 |
2023-11-02 |
The Broad Institute, Inc. |
Vecteurs aav codant pour des éditeurs de base et utilisations associées
|
|
WO2023240236A1
(fr)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions et procédés pour le traitement de troubles liés à l'amyotrophie spinale
|
|
WO2024040083A1
(fr)
|
2022-08-16 |
2024-02-22 |
The Broad Institute, Inc. |
Cytosine désaminases évoluées et méthodes d'édition d'adn l'utilisant
|
|
WO2024108092A1
(fr)
|
2022-11-17 |
2024-05-23 |
The Broad Institute, Inc. |
Distribution d'éditeur primaire par vaa
|
|
WO2024163012A1
(fr)
|
2023-02-02 |
2024-08-08 |
Voyager Therapeutics, Inc. |
Compositions et méthodes de traitement de troubles neurologiques liés à un déficit en bêta glucosylcéramidase
|
|
WO2025090858A1
(fr)
|
2023-10-27 |
2025-05-01 |
Biogen Ma Inc. |
Procédés d'identification de variants de capside de vaa ayant des caractéristiques souhaitées
|